{"id":7698,"date":"2020-06-24T08:24:00","date_gmt":"2020-06-24T08:24:00","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome\/"},"modified":"2020-06-24T08:24:00","modified_gmt":"2020-06-24T08:24:00","slug":"nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome\/","title":{"rendered":"Nicox : Conf\u00e9rence audio avec un leader d\u2019opinion cl\u00e9 sur le NCX 470 pour le traitement du glaucome"},"content":{"rendered":"<p>[vc_row][vc_column][vc_single_image image=\u00a0\u00bb324437&Prime; img_size=\u00a0\u00bbfull\u00a0\u00bb alignment=\u00a0\u00bbcenter\u00a0\u00bb image_hovers=\u00a0\u00bbfalse\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1592986979273{margin-top: 30px !important;margin-bottom: 30px !important;}\u00a0\u00bb][ultimate_spacer height=\u00a0\u00bb30&Prime;][vc_column_text]<\/p>\n<h4 style=\"text-align: center;\">Hosted by Nicox (EPA: COX)<\/h4>\n<p style=\"text-align: center;\">The call will feature a presentation by the current President of the American Glaucoma Society <strong>Dr. Donald Budenz, MD, MPH (Chair, Department of Ophthalmology, UNC Chapel Hill School of Medicine)<\/strong>\u00a0who will discuss the treatment landscape and unmet medical need in the treatment of glaucoma. Dr. Budenz will also discuss the results from the Dolomites Phase 2 trial with NCX 470, a novel, second generation nitric oxide-donating bimatoprost analog, in development for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. In this multicenter Phase 2 trial conducted in the U.S., NCX 470 demonstrated both statistical non-inferiority and superiority to latanoprost, the current U.S. standard of care for IOP lowering.<\/p>\n<p style=\"text-align: center;\">The Head of R&amp;D of the Nicox Group and General Manager of Nicox Ophthalmics, Inc., Tomas Navratil, PhD, will provide an overview of the recently initiated NCX 470 Mont Blanc Phase 3 trial as well as the plans for the Denali Phase 3 trial, which is expected to start before the end of 2020.<\/p>\n<p style=\"text-align: center;\">Nicox management and Dr. Budenz, MD, MPH will be available to answer questions at the conclusion of the call.<\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: center;\"><strong>Wednesday, June 24th 10:00 AM ET<\/strong><\/p>\n<p>[\/vc_column_text][dt_default_button link=\u00a0\u00bburl:http%3A%2F%2Fr20.rs6.net%2Ftn.jsp%3Ff%3D001xZsJh85hp1r6U_lt6jf4Ie-D6oGCr-8HMXwXa1McBJKFuRSfYbV7vLJFxKnQBn-fuVaIxwOwM3YoCpYoVBz7XrZ4Zxi6-aAwsgjkYd7jP7Aix6P6H0xnYO1PtRWhVCLK9pOgasFbXPDYGCZ7A82_U1uES6CXIl4BE622ACH59TJRflnYFQ54OaL0Mzw53vHX4oJDruVJHvAtvyV4m_-OqAzocY1793goOhOdJcAoIQToGPBnjPc6sdqNH1VZ9rV0C4b4MWzDlDJLjnrOxwjWigcDf2AFvUqT_M3UJ7rkHGc%3D%26c%3Dvn97VHKsXAMS93-nPdHhcvrMxEKQ-033G0VVE-S4tcf68WAIZU3UDA%3D%3D%26ch%3DOU11tVhXnxppi2P7FQcq_O3IEqAdQMUMXU-nhlrTmIlbs1JGnOeeTA%3D%3D||target:%20_blank|\u00a0\u00bb size=\u00a0\u00bbbig\u00a0\u00bb button_alignment=\u00a0\u00bbbtn_center\u00a0\u00bb animation=\u00a0\u00bbfadeInDown\u00a0\u00bb]Add to calendar[\/dt_default_button][vc_column_text css=\u00a0\u00bb.vc_custom_1592987009142{margin-top: 50px !important;}\u00a0\u00bb]<\/p>\n<h4 style=\"text-align: center;\">Dial-In &amp; Webcast Information<\/h4>\n<p style=\"text-align: center;\">Domestic: 1-877-705-6003<\/p>\n<p style=\"text-align: center;\">International: 1-201-493-6725<\/p>\n<p style=\"text-align: center;\">France toll free: 0 800 912 848<\/p>\n<p style=\"text-align: center;\">Conference ID: 13704934<\/p>\n<p>[\/vc_column_text][dt_default_button link=\u00a0\u00bburl:http%3A%2F%2Fr20.rs6.net%2Ftn.jsp%3Ff%3D001xZsJh85hp1r6U_lt6jf4Ie-D6oGCr-8HMXwXa1McBJKFuRSfYbV7vKOtvXRfpIJPn_vP17luH_znJr4sduIr0VvKfJEWD8O6uNDSrFBy-OkFay5q53j0jIO3J-_g0-3tRXwCnUijjlMUCeeLuBObfk9Eo7bKAUeiz4xAFb4KqUq3GD1kQW58ZA%3D%3D%26c%3Dvn97VHKsXAMS93-nPdHhcvrMxEKQ-033G0VVE-S4tcf68WAIZU3UDA%3D%3D%26ch%3DOU11tVhXnxppi2P7FQcq_O3IEqAdQMUMXU-nhlrTmIlbs1JGnOeeTA%3D%3D||target:%20_blank|\u00a0\u00bb size=\u00a0\u00bbbig\u00a0\u00bb button_alignment=\u00a0\u00bbbtn_center\u00a0\u00bb animation=\u00a0\u00bbfadeInDown\u00a0\u00bb]Enter webcast[\/dt_default_button][ultimate_spacer height=\u00a0\u00bb20&Prime;][vc_column_text]<\/p>\n<p style=\"text-align: center;\">For those who are unable to listen at this time, a replay of the call will be available by clicking\u00a0<a href=\"http:\/\/r20.rs6.net\/tn.jsp?f=001xZsJh85hp1r6U_lt6jf4Ie-D6oGCr-8HMXwXa1McBJKFuRSfYbV7vKOtvXRfpIJPn_vP17luH_znJr4sduIr0VvKfJEWD8O6uNDSrFBy-OkFay5q53j0jIO3J-_g0-3tRXwCnUijjlMUCeeLuBObfk9Eo7bKAUeiz4xAFb4KqUq3GD1kQW58ZA==&amp;c=vn97VHKsXAMS93-nPdHhcvrMxEKQ-033G0VVE-S4tcf68WAIZU3UDA==&amp;ch=OU11tVhXnxppi2P7FQcq_O3IEqAdQMUMXU-nhlrTmIlbs1JGnOeeTA==\" target=\"_blank\" rel=\"noopener noreferrer\">here<\/a>.<\/p>\n<p>[\/vc_column_text][vc_column_text css=\u00a0\u00bb.vc_custom_1592987020032{margin-top: 50px !important;}\u00a0\u00bb]<\/p>\n<h4 style=\"text-align: center;\">Q&amp;A Information<\/h4>\n<p style=\"text-align: center;\">If you would like to ask a question during the live Q&amp;A, please submit your request via email.<\/p>\n<p>[\/vc_column_text][dt_default_button link=\u00a0\u00bburl:mailto%3Aquestions%40lifesciadvisors.com||target:%20_blank|\u00a0\u00bb size=\u00a0\u00bbbig\u00a0\u00bb button_alignment=\u00a0\u00bbbtn_center\u00a0\u00bb animation=\u00a0\u00bbfadeInDown\u00a0\u00bb]Email Q&amp;A[\/dt_default_button][\/vc_column][\/vc_row][vc_row margin_top=\u00a0\u00bb50&Prime;][vc_column width=\u00a0\u00bb1\/4&Prime;][vc_column_text]<\/p>\n<h3><b>KOL Biography<\/b><\/h3>\n<p>[\/vc_column_text][vc_single_image image=\u00a0\u00bb324441&Prime; img_size=\u00a0\u00bbfull\u00a0\u00bb alignment=\u00a0\u00bbcenter\u00a0\u00bb image_hovers=\u00a0\u00bbfalse\u00a0\u00bb lazy_loading=\u00a0\u00bbtrue\u00a0\u00bb][\/vc_column][vc_column width=\u00a0\u00bb3\/4&Prime;][vc_column_text]<\/p>\n<h4>Donald Budenz, MD, MPH<\/h4>\n<p>Donald Budenz, MD, MPH, is the Kittner Family Distinguished Professor and Chairman, Department of Ophthalmology, UNC Chapel Hill School of Medicine, and President of the American Glaucoma Society. He has authored 230 peer-reviewed articles, numerous book chapters, and a single-authored textbook entitled Atlas of Visual Fields. His areas of research include clinical trials in glaucoma, imaging in glaucoma, and glaucoma epidemiology.[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_single_image image=\u00a0\u00bb324437&Prime; img_size=\u00a0\u00bbfull\u00a0\u00bb alignment=\u00a0\u00bbcenter\u00a0\u00bb image_hovers=\u00a0\u00bbfalse\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1592986979273{margin-top: 30px !important;margin-bottom: 30px !important;}\u00a0\u00bb][ultimate_spacer height=\u00a0\u00bb30&Prime;][vc_column_text] Hosted by Nicox (EPA: COX) The call will feature a presentation by the current President of the American Glaucoma Society Dr. Donald Budenz, MD, MPH (Chair, Department of Ophthalmology, UNC Chapel Hill School of Medicine)\u00a0who will discuss the treatment landscape and unmet medical need [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[16,33],"tags":[],"class_list":["post-7698","post","type-post","status-publish","format-standard","hentry","category-actualites-et-media","category-presentations-et-retransmissions"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox : Conf\u00e9rence audio avec un leader d\u2019opinion cl\u00e9 sur le NCX 470 pour le traitement du glaucome - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox : Conf\u00e9rence audio avec un leader d\u2019opinion cl\u00e9 sur le NCX 470 pour le traitement du glaucome - Nicox\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column][vc_single_image image=\u00a0\u00bb324437&Prime; img_size=\u00a0\u00bbfull\u00a0\u00bb alignment=\u00a0\u00bbcenter\u00a0\u00bb image_hovers=\u00a0\u00bbfalse\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1592986979273{margin-top: 30px !important;margin-bottom: 30px !important;}\u00a0\u00bb][ultimate_spacer height=\u00a0\u00bb30&Prime;][vc_column_text] Hosted by Nicox (EPA: COX) The call will feature a presentation by the current President of the American Glaucoma Society Dr. Donald Budenz, MD, MPH (Chair, Department of Ophthalmology, UNC Chapel Hill School of Medicine)\u00a0who will discuss the treatment landscape and unmet medical need [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-24T08:24:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox : Conf\u00e9rence audio avec un leader d\u2019opinion cl\u00e9 sur le NCX 470 pour le traitement du glaucome\",\"datePublished\":\"2020-06-24T08:24:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome\\\/\"},\"wordCount\":665,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s et M\u00e9dia\",\"Pr\u00e9sentations et retransmissions\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome\\\/\",\"name\":\"Nicox : Conf\u00e9rence audio avec un leader d\u2019opinion cl\u00e9 sur le NCX 470 pour le traitement du glaucome - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-06-24T08:24:00+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox : Conf\u00e9rence audio avec un leader d\u2019opinion cl\u00e9 sur le NCX 470 pour le traitement du glaucome - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox : Conf\u00e9rence audio avec un leader d\u2019opinion cl\u00e9 sur le NCX 470 pour le traitement du glaucome - Nicox","og_description":"[vc_row][vc_column][vc_single_image image=\u00a0\u00bb324437&Prime; img_size=\u00a0\u00bbfull\u00a0\u00bb alignment=\u00a0\u00bbcenter\u00a0\u00bb image_hovers=\u00a0\u00bbfalse\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1592986979273{margin-top: 30px !important;margin-bottom: 30px !important;}\u00a0\u00bb][ultimate_spacer height=\u00a0\u00bb30&Prime;][vc_column_text] Hosted by Nicox (EPA: COX) The call will feature a presentation by the current President of the American Glaucoma Society Dr. Donald Budenz, MD, MPH (Chair, Department of Ophthalmology, UNC Chapel Hill School of Medicine)\u00a0who will discuss the treatment landscape and unmet medical need [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome\/","og_site_name":"Nicox","article_published_time":"2020-06-24T08:24:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome\/"},"author":{"name":"","@id":""},"headline":"Nicox : Conf\u00e9rence audio avec un leader d\u2019opinion cl\u00e9 sur le NCX 470 pour le traitement du glaucome","datePublished":"2020-06-24T08:24:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome\/"},"wordCount":665,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s et M\u00e9dia","Pr\u00e9sentations et retransmissions"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome\/","url":"https:\/\/www.nicox.com\/fr\/nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome\/","name":"Nicox : Conf\u00e9rence audio avec un leader d\u2019opinion cl\u00e9 sur le NCX 470 pour le traitement du glaucome - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2020-06-24T08:24:00+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-conference-audio-avec-un-leader-dopinion-cle-sur-le-ncx-470-pour-traitement-du-glaucome\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7698"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7698\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}